ATE443763T1 - Behandlungs- und prophylaxeverfahren - Google Patents

Behandlungs- und prophylaxeverfahren

Info

Publication number
ATE443763T1
ATE443763T1 AT03792044T AT03792044T ATE443763T1 AT E443763 T1 ATE443763 T1 AT E443763T1 AT 03792044 T AT03792044 T AT 03792044T AT 03792044 T AT03792044 T AT 03792044T AT E443763 T1 ATE443763 T1 AT E443763T1
Authority
AT
Austria
Prior art keywords
inflammatory
treatment
prophylaxis
present
further provides
Prior art date
Application number
AT03792044T
Other languages
English (en)
Inventor
Kathryn Lawlor
Ian Wicks
Ian Campbell
Andrew Roberts
Donald Metcalf
Original Assignee
Inst Medical W & E Hall
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2002950957A external-priority patent/AU2002950957A0/en
Priority claimed from AU2002951071A external-priority patent/AU2002951071A0/en
Application filed by Inst Medical W & E Hall filed Critical Inst Medical W & E Hall
Application granted granted Critical
Publication of ATE443763T1 publication Critical patent/ATE443763T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Animal Husbandry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Rehabilitation Therapy (AREA)
AT03792044T 2002-08-23 2003-08-22 Behandlungs- und prophylaxeverfahren ATE443763T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2002950957A AU2002950957A0 (en) 2002-08-23 2002-08-23 A method of treatment and prophylaxis
AU2002951071A AU2002951071A0 (en) 2002-08-29 2002-08-29 A method of treatment and prophylaxis - II
PCT/AU2003/001078 WO2004017727A1 (en) 2002-08-23 2003-08-22 A method of treatment and prophylaxis

Publications (1)

Publication Number Publication Date
ATE443763T1 true ATE443763T1 (de) 2009-10-15

Family

ID=31947212

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03792044T ATE443763T1 (de) 2002-08-23 2003-08-22 Behandlungs- und prophylaxeverfahren

Country Status (12)

Country Link
US (1) US20060093604A1 (de)
EP (1) EP1542528B1 (de)
JP (1) JP4611738B2 (de)
AT (1) ATE443763T1 (de)
CA (1) CA2496485C (de)
DE (1) DE60329402D1 (de)
DK (1) DK1542528T3 (de)
ES (1) ES2333595T3 (de)
IL (1) IL167060A (de)
NZ (1) NZ538421A (de)
WO (1) WO2004017727A1 (de)
ZA (1) ZA200501629B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2056858T3 (da) 2006-08-11 2014-09-29 Csl Ltd Behandling af lungesygdomstilstande
KR101750426B1 (ko) * 2009-09-15 2017-06-23 씨에스엘 리미티드 신경 질환들의 치료
US20110117092A1 (en) * 2009-10-20 2011-05-19 The Regents Of The University Of Michigan Compositions and methods for inhibiting g-csfr
EP3580236A4 (de) * 2017-02-07 2020-12-09 ME Therapeutics Inc. Anti-g-csf-antikörper und verwendungen dafür
CN114755165B (zh) * 2022-04-21 2024-11-22 重庆医科大学附属第二医院 一种用于检测g-csfr的流式检测试剂及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE66494B1 (en) * 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
AU635377B2 (en) * 1989-11-21 1993-03-18 University Of Melbourne, The Anti-inflammatory compositions and methods
JP3525221B2 (ja) * 1993-02-17 2004-05-10 味の素株式会社 免疫抑制剤
US5420109A (en) * 1993-11-12 1995-05-30 Houghten Pharmaceuticals, Inc. Cytokine restraining agents
AUPM375094A0 (en) * 1994-02-08 1994-03-03 Ludwig Institute For Cancer Research Cytokine receptor interactive molecules and methods for assaying cytokine function
AUPM375194A0 (en) * 1994-02-08 1994-03-03 Ludwig Institute For Cancer Research Cytokine receptor interactive molecules
US5902584A (en) * 1994-02-08 1999-05-11 Ludwig Institute For Cancer Research Antibodies which bind the G-CSF receptor extracelluar domain and methods of treatment
US7108852B2 (en) * 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US6716811B1 (en) * 2000-07-20 2004-04-06 Affymax, Inc. Compounds having affinity for the granulocyte-colony stimulating factor receptor (G-CSFR) and associated uses
EP1317537B1 (de) * 2000-09-08 2006-12-20 Massachusetts Institute Of Technology Zusammensetzungen und verfahren mit analogen von g-csf

Also Published As

Publication number Publication date
NZ538421A (en) 2008-08-29
CA2496485C (en) 2014-07-15
WO2004017727A1 (en) 2004-03-04
DE60329402D1 (de) 2009-11-05
US20060093604A1 (en) 2006-05-04
EP1542528A1 (de) 2005-06-22
CA2496485A1 (en) 2004-03-04
ES2333595T3 (es) 2010-02-24
JP2005536535A (ja) 2005-12-02
EP1542528A4 (de) 2005-12-28
DK1542528T3 (da) 2010-02-01
EP1542528B1 (de) 2009-09-23
JP4611738B2 (ja) 2011-01-12
IL167060A (en) 2011-08-31
ZA200501629B (en) 2014-03-26

Similar Documents

Publication Publication Date Title
ATE416761T1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
DE60332358D1 (de) Protease-resistente modifizierte interferon alpha polypeptide
WO2003009855A3 (de) Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen
ATE444960T1 (de) Polyhydroxystilbene und -stilbenoxide als antipsoriasismittel und proteinkinasehemmer
DE60120691D1 (de) Zusammensetzungen zur verwendung bei der behandlung der osteoporose und/oder der entzündlichen gelenkerkrankungen
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
TW200512195A (en) Benzamide 2-hydroxy-3-diaminoalkanes
MXPA05005223A (es) Diaminotriazoles utiles como inhibidores de proteinas cinasas.
ATE544748T1 (de) Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
ATE401079T1 (de) Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
DE60329316D1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
ZA200809250B (en) Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
ATE451104T1 (de) Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen
MXPA05010958A (es) Derivados indazol como inhibidores jnk.
ATE471720T1 (de) Erhöhung des adenosin-spiegels durch cytokin- induzierte expression von cd73
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
UA86400C2 (ru) Применение эритропоэтина в низком дозировании для пациентов с дисфункцией эндотелиальных клеток-предшественников, сердечно-сосудистым фактором риска и повреждением конечного органа
MXPA05010515A (es) Tratamiento o prevencion de sofocos calientes utilizando profarmacos de analogos de gaba.
ATE443044T1 (de) Tace inhibitoren
DE60329402D1 (de) Behandlungs- und prophylaxeverfahren
BR0309122A (pt) Plantas com morfogênese melhorada e método para sua construção
NO20080781L (no) GLEPP-inhibitorer i behandlingen av autoimmune og/eller inflammatoriske sykdommer
DE60313803D1 (de) Cathepsincysteinproteaseinhibitoren und deren verwendung zur behandlung von entzündungen und immunerkrankungen
MX2023011012A (es) Compuestos farmaceuticos como inhibidores de proteasa 19 especifica de ubiquitina (usp19).
DK0674714T3 (da) Rekombinant gastrisk lipase fra hunde og farmaceutiske sammensætninger

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties